Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ESRRA | P11474 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27911606 | 0.98 | CA1 (0.56) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL30398809 | 0.85 | CA1 (0.59) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL14701729 | 0.85 | CA1 (0.56) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL28033864 | 0.85 | CA1 (0.56) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL27877288 | 0.84 | ESRRA (0.57) | CA1CA2CA9CA4ESRRA | |
| SCHEMBL69876 | 0.84 | ESRRA (0.62) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL3477570 | 0.83 | CA1 (0.57) | CA1CA2CA9CA4ESRRA | |
| SCHEMBL11902351 | 0.83 | CA1 (0.57) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL71817 | 0.83 | NOTUM (0.43) | CA1CA2CA9CA4NPC1 | |
| SCHEMBL28801446 | 0.82 | ESRRA (0.60) | CA1CA2CA9CA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398147-B2 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022240541-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3609504-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | Anacor Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018160845-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| CN-104603129-A | Triazole carboxamide derivatives | HOFFMANN LA ROCHE | 2015-05-06 | — | — | CN | disclosed |
| WO-2014041106-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| EP-2534170-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | Pharmascience Inc. (CA) | 2012-12-19 | — | — | EP | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011098904-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | WO | disclosed |
| US-20080200519-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008098798-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1958934-A1 | Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | TAAR1, HCRTR1, TAAR5 | CA1 2431/4885CA2 1361/4885CA9 3263/4885 |
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | CA1 1411/4885CA2 914/4885CA9 2004/4885 |
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | CA1 4880/4885CA2 4824/4885CA9 4366/4885 |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | CA1 4161/4885CA2 2080/4885CA9 2168/4885 |
| US-12398147-B2 | Macrocyclic spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | CA1 3740/4885CA2 1745/4885CA9 1594/4885 |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | OXA1L, AOX1, EPX | CA1 2840/4885CA2 1841/4885CA9 3215/4885 |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CA1 3367/4885CA2 3311/4885CA9 2677/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | CA1 1411/4885CA2 914/4885CA9 2004/4885 |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | CA1 3740/4885CA2 1745/4885CA9 1594/4885 |
| US-20080200519-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGES, PTGS1, PTGS2 | CA1 4137/4885CA2 2819/4885CA9 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.